Rasagiline binds to melanin, and its mechanism of action involves irreversible inhibition of monoamine oxidase subtype B (MAO-B) [22,23], increasing extracellular levels of dopamine, which is important in the treatment of PD [22,23,24,25]. Here, MAOB is linked to Parkinson disease.